RHHBY News Alert Roche Hldg Ltd Spons (RHHBY) 32.6050 02/15/2015
Post# of 64074
Posted On: 02/15/2015 11:41:14 AM
Roche Hldg Ltd Spons (RHHBY) 32.6050 $RHHBY
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - Seeking Alpha - 26 mins ago
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), QGEN: 23.68 (-0.06), CBMG: 24.32 (-1.17)
What are Penny Stocks?
Jordan Wathen, The Motley Fool - Motley Fool - Sun Feb 15, 6:00AM CST
New investors are often attracted to penny stocks due to the large opportunity for profits they seem to present. "If the shares can just trade up from $0.10 to $0.20 each, I'd double my money" is a popular line of thinking. But penny stocks are...
AMD: 3.15 (+0.03)
Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 14, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is currently the second-leading cause of death in the United States, and if the World Health Organization is correct, it may wind up eclipsing heart disease for the dubious top spot sometime in the near...
AZN: 69.96 (+0.20), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Why Regeneron's Risk-Reward Looks Good Again
DoctoRx - at Seeking Alpha - Thu Feb 12, 12:43PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Why Exelixis Inc.'s Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 10, 2:22PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Source: Exelixis What's Happening:...
EXEL: 2.48 (+0.20)
Pfenex up on Hospira biosimilar deal
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 9:05AM CST
PFNX: 12.45 (+0.29), HSP: 87.35 (unch)
Roche's Lucentis Gets FDA Nod for Diabetic Retinopathy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 5:04PM CST
Positive news flowed in for Roche (RHHBY) when it announced that the FDA has approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR) in patients suffering from diabetic macular edema (DME).
AGN: 229.49 (+1.87), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Glaxo Submits Another Revolade Application in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:54PM CST
GlaxoSmithKline (GSK) announced that it has submitted another marketing application for Revolade in the EU.
AGN: 229.49 (+1.87), LGND: 55.91 (-0.35), GSK: 47.94 (+1.99)
Roche Holding Falls 2.24% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 09, 3:55PM CST
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $32.78 to a high of $33.29. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $33.56 on volume of 11.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up
at Investor's Business Daily - Mon Feb 09, 3:53PM CST
One lesson to draw from recent M&A in the pharma space: Superbug drugs are hot. Last year, Actavis (ACT) plunked down $675 million for Durata Therapeutics, whose drug Dalvance fights some of the nastiest specimens of the class known as gram-positive...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), MDCO: 29.79 (+0.91), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Roche buys German genomics firm
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:01PM CST
Roche Holding Shares Down 13.4% Since SmarTrend's Sell Call (RHHBY)
Comtex SmarTrend(R) - Mon Feb 09, 9:56AM CST
SmarTrend identified a Downtrend for Roche Holding (NASDAQ:RHHBY) on February 27th, 2014 at $38.32. In approximately 12 months, Roche Holding has returned 13.43% as of today's recent price of $33.17.
AstraZeneca plc Beefs Up Precision Medicine Arsenal
Maxx Chatsko, The Motley Fool - Motley Fool - Mon Feb 09, 6:02AM CST
Novartis : "Hey, everyone, look over here. I just entered into a collaboration that will give me access to a pretty intriguing genome editing tool. Going to combine it with my top pipeline candidate . It's pretty cool." AstraZeneca : "I see your...
ALNY: 95.54 (+1.67), TMO: 127.61 (+0.78), AZN: 69.96 (+0.20), SGMO: 15.40 (+0.14), NVS: 102.20 (-0.17)
3 Medical Advancements You May Be Missing Out On
Motley Fool Staff - Motley Fool - Sun Feb 08, 10:02AM CST
Source: 3D Systems. From 3D printing to next-generation cancer killers, there are some medical innovations that could have an incredible impact on patients. Our Motley Fool analysts explain how these next-generation medical advances could reshape...
BIIB: 391.66 (-0.45), ONVO: 6.34 (+0.07), DDD: 32.81 (+0.40), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Fantastic News: A Revolutionary New Breast Cancer Drug Is on the Way
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 08, 8:12AM CST
Source: Komen Austin via Flickr . With the exception of skin cancer, breast cancer is the most commonly diagnosed type of cancer , making up one in every seven diagnoses in 2014 and nearly three in 10 cancer diagnoses for women. All told, that...
PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), GALE: 1.68 (+0.06), NVS: 102.20 (-0.17)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
FDA clears Lucentis for diabetic retinopathy
Seeking Alpha - at Seeking Alpha - Sat Feb 07, 10:53AM CST
In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 6:24AM CST
Macrophages attaching to a cancer cell. Source: Dr. Raowf Guirguis via Wikimedia Commons . Cancer is the second-leading cause of death in the United States, and if projections from the World Health Organization are correct about a nearly 60%...
IMGN: 7.19 (unch), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21)
FDA Approves Genentech's Lucentis(R) (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People With Diabetic Macular Edema
Business Wire - Fri Feb 06, 6:57PM CST
--Granted Breakthrough Therapy Designation and Priority Review by FDA
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - Seeking Alpha - 26 mins ago
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), QGEN: 23.68 (-0.06), CBMG: 24.32 (-1.17)
What are Penny Stocks?
Jordan Wathen, The Motley Fool - Motley Fool - Sun Feb 15, 6:00AM CST
New investors are often attracted to penny stocks due to the large opportunity for profits they seem to present. "If the shares can just trade up from $0.10 to $0.20 each, I'd double my money" is a popular line of thinking. But penny stocks are...
AMD: 3.15 (+0.03)
Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 14, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is currently the second-leading cause of death in the United States, and if the World Health Organization is correct, it may wind up eclipsing heart disease for the dubious top spot sometime in the near...
AZN: 69.96 (+0.20), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Why Regeneron's Risk-Reward Looks Good Again
DoctoRx - at Seeking Alpha - Thu Feb 12, 12:43PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Why Exelixis Inc.'s Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 10, 2:22PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Source: Exelixis What's Happening:...
EXEL: 2.48 (+0.20)
Pfenex up on Hospira biosimilar deal
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 9:05AM CST
PFNX: 12.45 (+0.29), HSP: 87.35 (unch)
Roche's Lucentis Gets FDA Nod for Diabetic Retinopathy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 5:04PM CST
Positive news flowed in for Roche (RHHBY) when it announced that the FDA has approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR) in patients suffering from diabetic macular edema (DME).
AGN: 229.49 (+1.87), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Glaxo Submits Another Revolade Application in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:54PM CST
GlaxoSmithKline (GSK) announced that it has submitted another marketing application for Revolade in the EU.
AGN: 229.49 (+1.87), LGND: 55.91 (-0.35), GSK: 47.94 (+1.99)
Roche Holding Falls 2.24% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 09, 3:55PM CST
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $32.78 to a high of $33.29. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $33.56 on volume of 11.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up
at Investor's Business Daily - Mon Feb 09, 3:53PM CST
One lesson to draw from recent M&A in the pharma space: Superbug drugs are hot. Last year, Actavis (ACT) plunked down $675 million for Durata Therapeutics, whose drug Dalvance fights some of the nastiest specimens of the class known as gram-positive...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), MDCO: 29.79 (+0.91), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Roche buys German genomics firm
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:01PM CST
Roche Holding Shares Down 13.4% Since SmarTrend's Sell Call (RHHBY)
Comtex SmarTrend(R) - Mon Feb 09, 9:56AM CST
SmarTrend identified a Downtrend for Roche Holding (NASDAQ:RHHBY) on February 27th, 2014 at $38.32. In approximately 12 months, Roche Holding has returned 13.43% as of today's recent price of $33.17.
AstraZeneca plc Beefs Up Precision Medicine Arsenal
Maxx Chatsko, The Motley Fool - Motley Fool - Mon Feb 09, 6:02AM CST
Novartis : "Hey, everyone, look over here. I just entered into a collaboration that will give me access to a pretty intriguing genome editing tool. Going to combine it with my top pipeline candidate . It's pretty cool." AstraZeneca : "I see your...
ALNY: 95.54 (+1.67), TMO: 127.61 (+0.78), AZN: 69.96 (+0.20), SGMO: 15.40 (+0.14), NVS: 102.20 (-0.17)
3 Medical Advancements You May Be Missing Out On
Motley Fool Staff - Motley Fool - Sun Feb 08, 10:02AM CST
Source: 3D Systems. From 3D printing to next-generation cancer killers, there are some medical innovations that could have an incredible impact on patients. Our Motley Fool analysts explain how these next-generation medical advances could reshape...
BIIB: 391.66 (-0.45), ONVO: 6.34 (+0.07), DDD: 32.81 (+0.40), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Fantastic News: A Revolutionary New Breast Cancer Drug Is on the Way
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 08, 8:12AM CST
Source: Komen Austin via Flickr . With the exception of skin cancer, breast cancer is the most commonly diagnosed type of cancer , making up one in every seven diagnoses in 2014 and nearly three in 10 cancer diagnoses for women. All told, that...
PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), GALE: 1.68 (+0.06), NVS: 102.20 (-0.17)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
FDA clears Lucentis for diabetic retinopathy
Seeking Alpha - at Seeking Alpha - Sat Feb 07, 10:53AM CST
In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 6:24AM CST
Macrophages attaching to a cancer cell. Source: Dr. Raowf Guirguis via Wikimedia Commons . Cancer is the second-leading cause of death in the United States, and if projections from the World Health Organization are correct about a nearly 60%...
IMGN: 7.19 (unch), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21)
FDA Approves Genentech's Lucentis(R) (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People With Diabetic Macular Edema
Business Wire - Fri Feb 06, 6:57PM CST
--Granted Breakthrough Therapy Designation and Priority Review by FDA
(0)
(0)Scroll down for more posts ▼